Document is current
Any future updates will be listed below
-
Authors
Becker, Maike https://orcid.org/0000-0001-6416-4213
Kälin, Stefanie
Neubig, Anne H. https://orcid.org/0000-0003-1770-6416
Lauber, Michael
Opaleva, Daria https://orcid.org/0000-0003-3947-7060
Hipp, Hannah
Salb, Victoria K.
Ott, Verena B.
Legutko, Beata
Kälin, Roland E.
Hippich, Markus https://orcid.org/0000-0001-6253-2596
Scherm, Martin G.
Nascimento, Lucas F. R.
Serr, Isabelle
Hosp, Fabian
Nikolaev, Alexei
Mohebiany, Alma https://orcid.org/0000-0001-9818-6867
Krueger, Martin
Flachmeyer, Bianca
Pfaffl, Michael W. https://orcid.org/0000-0002-3192-1019
Haase, Bettina https://orcid.org/0000-0002-9811-473X
Yi, Chun-Xia https://orcid.org/0000-0003-1184-4615
Dietzen, Sarah
Bopp, Tobias https://orcid.org/0000-0002-3232-8065
Woods, Stephen C.
Waisman, Ari https://orcid.org/0000-0003-4304-8234
Weigmann, Benno https://orcid.org/0000-0002-2398-0844
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
Daniel, Carolin https://orcid.org/0000-0003-4698-7069
- License Information
-
More Information
Article History
Received: 27 May 2022
Accepted: 7 March 2025
First Online: 20 March 2025
Competing interests
: As a scientist, M.H.T. participated in a scientific advisory board meeting of ERX Pharmaceuticals, Inc., Cambridge, MA, in 2019. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He consulted twice for Böhringer Ingelheim Pharma GmbH & Co. KG (2020 & 2021) and delivered a scientific lecture for Sanofi-Aventis Deutschland GmbH (2020) and for AstraZeneca GmbH (2024). As CEO and CSO of Helmholtz Munich, he is co-responsible for countless collaborations of the employees with a multitude of companies and institutions, worldwide. In this capacity, he discusses potential projects with and has signed/signs contracts for the centers institute(s) related to research collaborations worldwide, including but not limited to pharmaceutical corporations like Boehringer Ingelheim, Novo Nordisk, Roche Diagnostics, Arbormed, Eli Lilly, SCG Cell Therapy and others. As the CEO of Helmholtz Munich, he was/is further overall responsible for commercial technology transfer activities. M.H.T. confirms that to the best of his knowledge, none of the above funding sources or collaborations were involved in or had an influence on the preparation of this manuscript. The remaining authors declare no competing interests.
